Appeals run in two stages. The first is internal, filed with the health plan inside the deadline printed on the denial notice. If that stage fails and the denial turned on medical judgment, federal rules entitle the member to an independent external review by an organization outside the plan. Members with Medicare coverage follow a separate ladder set by CMS.
Only some decisions are appealable
An appeal challenges a determination the plan made. It does not rewrite what the plan was sold to cover. If an employer group purchased coverage that excludes weight management drugs, the denial is a contract term rather than a judgment, and no level of the process reaches it. Members who spend three months appealing an exclusion nearly always started without checking the benefit document.
Denials that do open the ladder involve medical necessity, clinical criteria, experimental or investigational determinations, and disputes about whether a requested drug fits a covered category. External review exists precisely because those calls involve judgment, and judgment made entirely inside one organization deserves a second look from outside it.
Stage one: the internal appeal
The internal appeal goes to the health plan, not to the clinic. The notice names the address, the filing window and the form of the request, and those deadlines are enforced. Federal standards for group and individual coverage require plans to review the case fully and fairly, and to have the review conducted by someone who was not involved in the original decision and does not report to whoever was.
That last requirement carries extra weight in an integrated organization, where the original reviewer, the prescriber and the pharmacy all share an employer. A member is entitled to ask, in writing, who conducted the review and what specialty they hold. It is a fair question, and it is answerable.
Stage two: independent external review
External review moves the file to reviewers outside the plan whose decision the plan must follow. The federal framework was built into the health care law so that a member facing a clinical denial is not left with the insurer as the last word. Depending on the plan and the state, the review runs through a state process or the federal one, and the notice from the internal decision states which applies.
Two details matter. The window to request external review is short and starts from the final internal decision. And an expedited path exists when waiting for the standard timeline would seriously jeopardize health, which can be requested at the same time as an expedited internal appeal rather than after it.
Medicare coverage follows a different ladder
| Coverage type | First step | Next step | Independent stage |
|---|---|---|---|
| Employer group or individual commercial | Internal appeal to the health plan | Second internal level where the plan offers one | External review by an outside organization |
| Medicare drug coverage | Coverage determination request | Redetermination by the plan | Independent review entity under CMS rules |
| Medicare Advantage | Organization determination | Plan reconsideration | Independent review, then further CMS levels |
| Any of the above, urgent | Expedited request with prescriber support | Shortened decision clock | Expedited independent review |
The Medicare tracks add levels above the independent stage, running to an administrative law judge and beyond. Few weight management disputes travel that far, but the ladder exists and the deadlines at each rung are published by CMS.
The clinician on the file is also inside the plan
This cuts both ways and it is worth naming honestly. A supporting statement from the treating physician is the single most valuable document in a clinical appeal, and in an integrated system that physician is a colleague of the reviewer with direct access to the same record. Getting the statement written and attached is usually faster than it would be across two companies.
What a member does not get, until external review, is a reviewer with no institutional relationship to the decision. Knowing that shapes strategy. It argues for putting the strongest possible clinical case into the internal stage, then treating external review as the real hearing rather than a formality nobody expects to reach.
None of that changes what happens at the pharmacy in the meantime, which is where the interim cost enters. What a self-pay bridge runs varies by provider, so it rewards a quick comparison: LillyDirect sells the branded drug straight from the maker, Ro and Hims and Hers advertise monthly rates, and HealthRX maintains a page for Wegovy that lists the cash price up front.
An appeal needs something the first submission did not have
Resubmitting the same file with a firmer tone changes nothing. Read the denial for the exact criterion that failed and answer that criterion specifically. Weight measurements with dates rather than recollections. A record of what was tried before and why it stopped. Comorbid conditions documented in the chart rather than mentioned in a letter. Notes on why an alternative on the drug list is unsuitable for this person, if that is the argument.
Continuity is a legitimate clinical argument in its own right for anyone already established on treatment. Weight regain after these drugs are stopped is documented in the literature, so an interruption forced by paperwork has a foreseeable consequence, and saying so plainly is stronger than asserting general benefit.
What happens to treatment while the appeal runs
Nothing is released at the pharmacy during an appeal, which is why households make a separate decision about the gap. Buying the approved product at the manufacturer’s published self-pay price is the reference option, since it is the same medication with the same label. Membership services including Ro, LifeMD, Hims and Hers and FormBlends instead dispense compounded semaglutide, which is not FDA approved and has not been reviewed by the agency for safety, effectiveness or quality. Choosing either one does not weaken an appeal in progress, provided doses, dates and weights are recorded, because that record is what a reviewer can use later.
Frequently asked questions
How long is there to file?
The filing window appears on the denial notice and is measured from the date of that notice. Commercial internal appeals commonly allow months, while external review windows are considerably shorter and run from the final internal decision. Missing either deadline usually ends the matter regardless of the merits.
Does an external reviewer have to follow the plan’s own criteria?
Reviewers weigh the plan’s terms alongside clinical evidence and accepted practice standards. That is the point of the stage. A criterion applied inconsistently with medical evidence is exactly the kind of question an outside reviewer is positioned to examine, and the plan is bound by the result.
Can someone else file on a member’s behalf?
Yes. A member can appoint a representative, commonly the prescribing clinician or a family member, usually with a signed authorization form. Naming the prescriber as representative is practical, since that person holds the clinical record the appeal depends on and can respond to questions directly.
Is a grievance the same as an appeal?
No. A grievance concerns service quality, access or conduct, and it does not change a coverage decision. Filing a grievance about a denial feels productive and accomplishes nothing on the coverage question, so the two should be filed separately when both are warranted.
What if the plan misses its own deadline?
Failure to follow the required process can allow a member to move to the next stage without waiting for the overdue decision. Documenting submission dates and confirmation numbers is what makes that argument available, so keeping a dated log from the first day is worth the small effort.
